Conjupram Drug Interactions

Escitalopram has a low potential for clinically significant medicine interactions. In vitro studies have shown that the biotransformation of escitalopram to its demethylated metabolites depends on three parallel pathways (cytochrome P450, 2C19, 3A4 and 2D6). Escitalopram is very weak inhibitor of isoenzyme CYP1A2, 2C9, 2C19,2E1 and 3A.
Ritonavir - The pharmacokinetics of single doses of Escitalopram was not changed by co-administration with single dose of ritonavir (CYP3A4 inhibitor). Ketoconazole - Co-administration with ketoconazole (potent CYP3A4 inhibitor) did not change the pharmacokinetics of racemix citalopram. MAOI, Sumatriptan and Tramadol - Co-administration with MAO inhibitors may cause serotonin syndrome. Co-administration with other serotogenic medicines (e.g. tramadol, sumatriptan) as well as other antidepressants with serotogenic properties may lead to an enhancement of serotonin associated, e.g. serotonin syndrome.